Role of Chromogranin A and Neuron-Specific Enolase Biomarkers in Progression-Free Survival (PFS) with Everolimus (EVE) versus Placebo (PB) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET) : Phase III RADIANT-3 Results

作者： K. Oberg , R. Winkler , de Elisabeth G. E. Vries , L. Anthony , L. T. Chen